Literature DB >> 17028598

A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes.

O A Kent1, J T Mendell.   

Abstract

The known classes of genes that function as tumor suppressors and oncogenes have recently been expanded to include the microRNA (miRNA) family of regulatory molecules. miRNAs negatively regulate the stability and translation of target messenger RNAs (mRNA) and have been implicated in diverse processes such as cellular differentiation, cell-cycle control and apoptosis. Examination of tumor-specific miRNA expression profiles has revealed widespread dysregulation of these molecules in diverse cancers. Although studies addressing their role in cancer pathogenesis are at an early stage, it is apparent that loss- or gain-of-function of specific miRNAs contributes to cellular transformation and tumorigenesis. The available evidence clearly demonstrates that these molecules are intertwined with cellular pathways regulated by classical oncogenes and tumor suppressors such as MYC, RAS and p53. Incorporation of miRNA regulation into current models of molecular cancer pathogenesis will be essential to achieve a complete understanding of this group of diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17028598     DOI: 10.1038/sj.onc.1209913

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  327 in total

1.  Functional genomics of tumor suppressor miR-196b in T-cell acute lymphoblastic leukemia.

Authors:  Suman Bhatia; Deepak Kaul; Neelam Varma
Journal:  Mol Cell Biochem       Date:  2010-10-06       Impact factor: 3.396

2.  Low expression of miR-let-7a promotes cell growth and invasion through the regulation of c-Myc in oral squamous cell carcinoma.

Authors:  Chunyang Luo; Jiyong Zhang; Yi Zhang; Xiao Zhang; Yinan Chen; Weimin Fan
Journal:  Cell Cycle       Date:  2020-06-28       Impact factor: 4.534

Review 3.  MicroRNA, nutrition, and cancer prevention.

Authors:  Sharon A Ross; Cindy D Davis
Journal:  Adv Nutr       Date:  2011-11-03       Impact factor: 8.701

4.  Applications of microRNA in cancer: Exploring the advantages of miRNA.

Authors:  Scott A Waldman; Andre Terzic
Journal:  Clin Transl Sci       Date:  2009-06       Impact factor: 4.689

5.  MicroRNA cloning and sequencing in osteosarcoma cell lines: differential role of miR-93.

Authors:  Luisa Montanini; Lisa Lasagna; Valeria Barili; Søren Peter Jonstrup; Alba Murgia; Laura Pazzaglia; Amalia Conti; Chiara Novello; Jørgen Kjems; Roberto Perris; Maria Serena Benassi
Journal:  Cell Oncol (Dordr)       Date:  2011-09-30       Impact factor: 6.730

Review 6.  The impact of the Cancer Genome Atlas on lung cancer.

Authors:  Jeremy T-H Chang; Yee Ming Lee; R Stephanie Huang
Journal:  Transl Res       Date:  2015-08-10       Impact factor: 7.012

7.  High Expression of miR-532-5p, a Tumor Suppressor, Leads to Better Prognosis in Ovarian Cancer Both In Vivo and In Vitro.

Authors:  Fan Wang; Jeremy T-H Chang; Chester Jingshiu Kao; R Stephanie Huang
Journal:  Mol Cancer Ther       Date:  2016-02-12       Impact factor: 6.261

8.  Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma.

Authors:  Geoffrey Childs; Melissa Fazzari; Gloria Kung; Nicole Kawachi; Margaret Brandwein-Gensler; Michael McLemore; Quan Chen; Robert D Burk; Richard V Smith; Michael B Prystowsky; Thomas J Belbin; Nicolas F Schlecht
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

Review 9.  Emergence of Circulating MicroRNAs in Breast Cancer as Diagnostic and Therapeutic Efficacy Biomarkers.

Authors:  Vaishali Aggarwal; Kumari Priyanka; Hardeep Singh Tuli
Journal:  Mol Diagn Ther       Date:  2020-04       Impact factor: 4.074

Review 10.  MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine.

Authors:  Prasun J Mishra; Joseph R Bertino
Journal:  Pharmacogenomics       Date:  2009-03       Impact factor: 2.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.